IgGs from patients with amyotrophic lateral sclerosis and diabetes target Ca<sub>V</sub>α<sub>2</sub>δ1 subunits impairing islet cell function and survival.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31826954.
- Also identified by DOI 10.1073/pnas.1911956116 and PMC identifier 6936400.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with amyotrophic lateral sclerosis (ALS) often show hallmarks of type 2 diabetes mellitus (T2DM). However, the causal link between ALS and T2DM has remained a mystery. We now demonstrate that 60% of ALS patients with T2DM (ALS-T2DM) have sera that exaggerated K<sup>+</sup>-induced increases in cytosolic free Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) in mouse islet cells. The effect was attributed to the presence of pathogenic immunoglobulin Gs (IgGs) in ALS-T2DM sera. The pathogenic IgGs immunocaptured the voltage-dependent Ca<sup>2+</sup> (Ca<sub>V</sub>) channel subunit Ca<sub>V</sub>α<sub>2</sub>δ1 in the plasma membrane enhancing Ca<sub>V</sub>1 channel-mediated Ca<sup>2+</sup> influx and [Ca<sup>2+</sup>]<sub>i</sub>, resulting in impaired mitochondrial function. Consequently, impairments in [Ca<sup>2+</sup>]<sub>i</sub> dynamics, insulin secretion, and cell viability occurred. These data reveal that patients with ALS-T2DM carry cytotoxic ALS-T2DM-IgG autoantibodies that serve as a causal link between ALS and T2DM by immunoattacking Ca<sub>V</sub>α<sub>2</sub>δ1 subunits. Our findings may lay the foundation for a pharmacological treatment strategy for patients suffering from a combination of these diseases.